SCHEMBL4867460

SCHEMBL4867460

COC(=O)C1=C(O)c2c(cccc2NC(C)=O)CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SLC6A3 Q01959 6/20 0.40
ABCB1 P08183 1/20 0.40
MAOA P21397 1/20 0.40
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337358 0.77 BAZ2B (0.49) NPC1RAB9AMAOAALDH1A1HSD17B10
SCHEMBL21098726 0.76 NPC1 (0.46) NPC1RAB9AMAOAALDH1A1HSD17B10
SCHEMBL4877329 0.75 MAOA (0.49) NPC1RAB9AMAOAALDH1A1HSD17B10
SCHEMBL22815827 0.73 SMN1; SMN2 (0.43) NPC1RAB9AMAOAALDH1A1HSD17B10
SCHEMBL30567324 0.72 ALDH1A1 (0.68) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL1613763 0.72 ALDH1A1 (0.68) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL1612079 0.71 MAOA (0.51) NPC1RAB9AMAOAALDH1A1HSD17B10
SCHEMBL20136607 0.71 CA12 (0.40) NPC1RAB9ASLC6A3ABCB1ALDH1A1
SCHEMBL20136606 0.71 SLC6A3 (0.42) NPC1RAB9ASLC6A3ALDH1A1GAA
SCHEMBL1638724 0.69 ALDH1A1 (0.72) NPC1RAB9AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735411-B2 Macrocyclic benzofused pyrimidine derivatives ABBVIE INC. (US) 2014-05-27 US disclosed
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives ABBVIE INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives DPYD, TYMS, UMPS NPC1 313/4885RAB9A 3539/4885SLC6A3 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.